Skip to content

Venture

Bow Therapeautics Logo

Affiliations

Albert Einstein College of Medicine

Technologies

Therapeutic

Indication

Autoimmune & Inflammation

Drug Discovery

Infectious Disease

Bow Therapeutics is developing isolation of human monoclonal antibodies against Chikungunya Virus Glycoprotein using Single B-cell sorting Technology.

 

Bow Therapeutics Team:

George Georgiev

Jose Quiroz